Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-8294 Monotherapy in Advanced Solid Tumors
NCT07030712Phase 1Recruiting
- Sponsor
- Merck & Co.
- Start
- Jul 2025
- Primary completion
- Jul 2029
- Countries
- 3
01
Overview
Phase 1, open-label, single-arm trial of MK-8294 in solid tumor, sponsored by Merck & Co. Primary endpoints: Dose-Limiting Toxicities at 35 days, Adverse Events at 2 years and 1 more. Started Jul 2025; status: recruiting.
02
Drugs
MK-8294
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07030712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07030712.